Therapeutic Asset Ratings

13,157 results matching 1 filter

91,583 assets · 7,906 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Nivolumab Urinary Bladder Cancer	M.D. Anderson Cancer Center	P2	B (63)
Nivolumab Rectal Cancer	Odense University Hospital	P2	B (63)
Nivolumab Stage IVb Bladder Cancer	M.D. Anderson Cancer Center	P2	B (63)
NOGITECAN Malignant Glioma	Jeffrey N. Bruce	P2	B (63)
Obinutuzumab Indolent B-Cell Non-Hodgkin Lymphoma	Reid Merryman, MD	P2	B (63)
Obinutuzumab Lymphoplasmacytic Lymphoma	Emory University	P2	B (63)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Primary Peritoneal Carcinoma	Mayo Clinic	P2	B (63)
ONDANSETRON B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma	UNC Lineberger Comprehensive Cancer Center	P2	B (63)
OXALIPLATIN Digestive System Cancer	Alliance for Clinical Trials in Oncology	P2	B (63)
OXALIPLATIN Richter Transformation	National Heart, Lung, and Blood Institute (NHLBI)	P2	B (63)
PEGFILGRASTIM Peripheral T-Cell Lymphoma, Not Otherwise Specified	City of Hope Medical Center	P2	B (63)
PEGFILGRASTIM B-Cell Acute Lymphoblastic Leukemia	University of Washington	P2	B (63)
Pembrolizumab B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma	Seda S. Tolu	P2	B (63)
Pembrolizumab Fallopian Tube Serous Adenocarcinoma	Roswell Park Cancer Institute	P2	B (63)
Pembrolizumab Gallbladder Cancer	Merck Sharp & Dohme LLC	P2	B (63)
Pembrolizumab Hormone-Resistant Prostate Carcinoma	University of Wisconsin, Madison	P2	B (63)
Pembrolizumab Marginal Zone Lymphoma	University of Ulm	P2	B (63)
Pembrolizumab Myxoid Liposarcoma	Valo Therapeutics Oy	P2	B (63)
Pembrolizumab Ovarian Clear Cell Adenocarcinoma	Roswell Park Cancer Institute	P2	B (63)
Pembrolizumab Pancreatic Adenocarcinoma	Mayo Clinic	P2	B (63)
Pembrolizumab Primary Peritoneal Serous Adenocarcinoma	Roswell Park Cancer Institute	P2	B (63)
Pembrolizumab Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Mayo Clinic	P2	B (63)
Pembrolizumab High Grade B-Cell Lymphoma	Mayo Clinic	P2	B (63)
Pembrolizumab Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma	City of Hope Medical Center	P2	B (63)
Pembrolizumab Sarcoma	Essen Biotech	P2	B (63)

Showing 1051 to 1075 of 13,157 assets

PreviousPage 43 of 527Next